The Research Training Program (RTP) in Urologic Oncology at MSKCC is designed to train academic leaders in urologic oncology. Over 180 fellows have been trained since the fellowship program was established nearly 50 years ago. Each year 8-15 highly qualified candidates are interviewed from a pool of 25-40 applicants, 3-9 are accepted as post-doctoral fellows, all board-eligible urologists who have completed residency. Two of these are selected each year as research career awardees supported by our T32 training grant, initially funded in 1999, to spend 2 years in research with a senior scientist mentor at MSKCC, Weill Medical College of Cornell University or Rockefeller University, in an appropriate field such as immunology, biological imaging, molecular genetics, or biostatistics. Specific research projects have included adoptive immunotherapy with genetically modify T lymphocytes, monoclonal antibodies against PSMA as imaging and therapeutic agents, and gene expression analysis of prostate cancers. Of 11 fellows appointed to date, 4 are in training, 7 have graduated, and 6 are now assistant professors at major universities. Fellows are required to participate in structured, multidisciplinary clinical and research conferences and to present their work at MSKCC seminars and national meetings. They receive formal instruction in clinical research methodology, biostatistics, research ethics, and human subjects regulatory issues. Our program has grown substantially since the original award. The faculty in urology has doubled, the quality and diversity of research mentors has increased and the number and quality of fellowship applicants have grown steadily. The RTP in urologic oncology is essential to our fellowship, supporting urologists committed to research training to prepare for a career as independent investigators. Our experience over 50 years confirms that they will become leaders of urologic oncology in the next generation whose work will help decrease morbidity from GU cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA082088-10
Application #
7663755
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
1999-09-01
Project End
2010-08-12
Budget Start
2009-03-01
Budget End
2010-08-12
Support Year
10
Fiscal Year
2009
Total Cost
$243,527
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Lee, Byron H; Feifer, Andrew; Feuerstein, Michael A et al. (2018) Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma. Eur Urol Focus 4:100-105
Mendonca, Shawn J; Sanchez, Alejandro; Blum, Kyle A et al. (2018) The association of renal cell carcinoma with gastrointestinal stromal tumors. J Surg Oncol 117:1716-1720
Becerra, Maria F; Reznik, Ed; Redzematovic, Almedina et al. (2018) Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. Eur Urol Focus 4:986-994
Kashan, Mahyar; Ghanaat, Mazyar; Hötker, Andreas M et al. (2018) Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging. J Urol 200:275-282
Isharwal, Sumit; Huang, Hongying; Nanjangud, Gouri et al. (2018) Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Hum Pathol 77:63-69
Isharwal, Sumit; Audenet, François; Drill, Esther et al. (2017) Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. Eur Urol Focus :
Casuscelli, Jozefina; Becerra, Maria F; Manley, Brandon J et al. (2017) Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. Eur Urol Focus :
Manley, Brandon J; Reznik, Ed; Ghanaat, Mazyar et al. (2017) Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. Urol Oncol :
Manley, Brandon John; Zabor, Emily C; Casuscelli, Jozefina et al. (2017) Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. Eur Urol Focus 3:421-427
Casuscelli, Jozefina; Weinhold, Nils; Gundem, Gunes et al. (2017) Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. JCI Insight 2:

Showing the most recent 10 out of 202 publications